Evolution of diabetes technology

In view of the current accelerating pace of diabetes technology development, ever smaller and more accurate CGM sensors, novel implantable sensors for long-term use (>1 year) with no on-body components, and CGM devices with increased connectivity and improved data visualization both on the device and remotely through the cloud can be anticipated. Automated systems for insulin delivery will become more independent and will likely incorporate other physiologic and behavioral data for providing more accurate predictions, particularly related to food and physical activity. With the increasing technical complexity, DSSs will become an inevitable part of digital diabetes clinics, including their use at the primary care level. In addition, all will depend on the cost-effectiveness that will drive the access and reimbursement of different technologies, and ultimately on the acceptance of any particular technology by individuals with diabetes. TIR is being validated as a new clinical marker, and simple clinical guidance on TIR targets and data visualization were broadly endorsed by professionals, and are being introduced to individuals with diabetes. However, the ultimate goal of diabetes technology development remains clear: improved diabetes outcomes with reduced disease burden and increased QOL for all individuals with diabetes and their families